Genprex Inc

Genprex operates with a capital structure that is entirely equity-funded, as evidenced by a debt-to-equity ratio of 0.0 and no long-term debt. The company's liquidity position is characterized by a current ratio of 1.95, indicating that it has sufficient current assets to cover its current liabilities. However, the liquidity risk is assessed as low, suggesting that the company is not currently facing immediate liquidity constraints. Profitability metrics for Genprex are negative, with a return on equity of -1.4948 and a return on assets of -0.9835. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets to generate profit. The company's price-to-book ratio of 2.1 suggests that the market is valuing the company at a premium to its book value, despite the negative returns. The company's revenue concentration is not disclosed in the available data, but as a clinical-stage biotechnology firm, it is likely that its operations are focused on a limited number of therapeutic areas and geographic regions. This concentration could pose a risk if the company's lead candidates fail in clinical trials or if regulatory approvals are delayed. Genprex's growth trajectory is not clearly defined in the available data, but the company's negative operating and net income figures suggest that it is not currently generating revenue from operations. The company's outlook for the current fiscal year is not provided, but the absence of positive financial performance indicators implies that the company is in an early stage of development and may require additional capital to fund its operations. The risk assessment for Genprex indicates a low level of dilution risk, with no immediate filing-based liquidity or dilution flags detected. The company's dilution potential is also assessed as low, suggesting that there is no significant threat to shareholder value from new equity issuances. The company's financial structure and the absence of dilution risks are positive factors for investors. Recent events for Genprex include the continued development of its clinical-stage pipeline, with no significant filings or transcripts indicating major changes in the company's strategic direction. The company's ESG score of 19.39 and a D+ grade suggest that it has room for improvement in its environmental, social, and governance practices. The governance pillar score of 10.47 is particularly low, indicating potential concerns in this area.